Drug Trial Radar · NCT04784052
Depleted Donor Stem Cell Transplant in Children and Adults With Fanconi Anemia After Being Conditioned With a Regimen Containing Briquilimab
Last checked: Nov 19, 2026Latest source record: Jan 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
18
Planned (sponsor's estimate)
Start
Dec 7, 2021
Primary completion
Dec 2027
Study completion Dec 2028
Sponsor
- Lead sponsor
- Porteus, Matthew, MDAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Mar 5, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 2 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of this clinical trial is to develop a cell therapy for Fanconi Anemia which enables enhanced donor hematopoietic and immune reconstitution with decreased toxicity by transplanting depleted stem cells from a donor with and without using an experimental antibody treatment called JSP-191 as a part of conditioning. This experimental treatment will hopefully cause fewer side effects than chemotherapy (the current standard of care method). Participants will be administered the conditioning regimen, are assessed until they receive the depleted stem cell infusion, and will be followed for up to 2 years after the cell infusion.
Conditions
- Fanconi Anemia
Interventions
JSP191Drug
Participants will receive a single IV dose at start of conditioning
CliniMACS Prodigy SystemDevice
The device used to remove the αβ+T cells from donor stem cell transplant before being given to the recipient
Depleted Stem Cell TransplantBiological
TCRαβ+ T-cell/CD19+ B-cell depleted hematopoietic cells will be administered by IV after completion of conditioning regimen.
Rabbit Anti-Thymoglobulin (rATG)Biological
3 consecutive daily doses of rATG will be given by IV during conditioning
CyclophosphamideDrug
4 consecutive daily doses of cyclophosphamid will be given by IV during conditioning
FludarabineDrug
4 consecutive daily doses of fludarabine will be given by IV during conditioning
RituximabDrug
1 dose of rituximab will be given at the end of conditioning
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants without grade 3 and 4 treatment-emergent adverse events (TEAEs) (infusion related reactions).Time frame: From start of conditioning regimen administration until cell infusion (up to 30 days)
- Number of participants without grade 3 and 4 treatment-emergent adverse events (TEAEs) (infusion related reactions) following infusion of TCRαβ+ T-cell/CD19+ B-cell depleted hematopoietic graft transplantationTime frame: Up to 2 years post-cell infusion
- Number of participants able to achieve donor engraftmentTime frame: Assessed at Day +42 post-cell infusion
- Number of participants who are able to have donor engraftment persist at the same rate or better compared to alternative hematopoietic cell transplant regimens for this patient populationTime frame: Assessed at Day +100 post-cell infusion
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Stanford University
Stanford, California · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.